Loading…

Botulinum Toxin in the Treatment of Neurological Disorders

Botulinum toxin therapy is safe and effective in the treatment of different movement disorders, especially focal dystonias. We reviewed botulinum toxin treatment of 97 patients: 36 had blepharospasm, 41 had torticollis, and 20 had diverse movement disorders. Patients with blepharospasm and torticoll...

Full description

Saved in:

Bibliographic Details
Published in:	Annals of the New York Academy of Sciences 1994-01, Vol.710 (1), p.76-87
Main Authors:	DENIŠLIČ, MIRO, PIRTOŠEK, ZVEZDAN, VODUŠEK, DAVID B., ZIDAR, JANEZ, MEH, DUŠKA
Format:	Article
Language:	English
Subjects:	Adolescent Adult Aged Aged, 80 and over Blepharospasm - drug therapy Blepharospasm - physiopathology Botulinum Toxins - adverse effects Botulinum Toxins - therapeutic use Child Clostridium botulinum Female Humans Male Middle Aged Movement Disorders - drug therapy Movement Disorders - physiopathology Torticollis - drug therapy Torticollis - physiopathology
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-c5336-170c29ba23e652546eb2e133b0ff804e37c14f4fce4ed1e2394bae5165206ee23
cites	cdi_FETCH-LOGICAL-c5336-170c29ba23e652546eb2e133b0ff804e37c14f4fce4ed1e2394bae5165206ee23
container_end_page	87
container_issue	1
container_start_page	76
container_title	Annals of the New York Academy of Sciences
container_volume	710
creator	DENIŠLIČ, MIRO PIRTOŠEK, ZVEZDAN VODUŠEK, DAVID B. ZIDAR, JANEZ MEH, DUŠKA
description	Botulinum toxin therapy is safe and effective in the treatment of different movement disorders, especially focal dystonias. We reviewed botulinum toxin treatment of 97 patients: 36 had blepharospasm, 41 had torticollis, and 20 had diverse movement disorders. Patients with blepharospasm and torticollis improved markedly after botulinum toxin injections. The most common side effect in BS patients was ptosis (44.4%); in TC patients, it was dysphagia (29.3%). The mean duration of the improvement in both groups was 3.4 months. Very promising results were obtained also in the heterogeneous group including patients with other focal dystonias and cerebral palsy. On the basis of these results, we concluded that BTA injections must now be considered the mainstay of therapy for focal dystonias and other involuntary movement disorders.
doi_str_mv	10.1111/j.1749-6632.1994.tb26615.x
format	article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16994491</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16994491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5336-170c29ba23e652546eb2e133b0ff804e37c14f4fce4ed1e2394bae5165206ee23</originalsourceid><addsrcrecordid>eNqVkF1r2zAUhsXW0aVZfkLB7GJ3dnX0afVi0O8WSnYxj7ErYTvHnTM7SiWbJf--Cgm5rxAI8b7nOfAQ8hVoBvFcLDPQwqRKcZaBMSIbKqYUyGzzgUyO0UcyMzqnudFK5ZLBCZlQqnWaG8Y_k7MQlpQCy4U-Jac5SKEVn5DLazeMXbsa-6Rwm3aVxDv8xaTwWA49robENckcR-8699LWZZfctsH5BfrwhXxqyi7g7PBOya_7u-LmMX3-8fB0c_Wc1pJzlYKmNTNVyTgqyaRQWDEEzivaNDkVyHUNohFNjQIXgIwbUZUoIZapwvifkm977tq71xHDYPs21Nh15QrdGCyoqEQYiMXLfbH2LgSPjV37ti_91gK1O5F2aXe27M6W3Ym0B5F2E4fPD1vGqsfFcfRgKubf9_n_tsPtO8h2_ufqZyRMSboHtGHAzRFQ-n9Waa6l_T1_sLIQcaEBW_A3Lv6O_A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16994491</pqid></control><display><type>article</type><title>Botulinum Toxin in the Treatment of Neurological Disorders</title><source>Wiley-Blackwell Journals (Backfile Content)</source><creator>DENIŠLIČ, MIRO ; PIRTOŠEK, ZVEZDAN ; VODUŠEK, DAVID B. ; ZIDAR, JANEZ ; MEH, DUŠKA</creator><contributor>Zorec, R (eds) ; Suput, D</contributor><creatorcontrib>DENIŠLIČ, MIRO ; PIRTOŠEK, ZVEZDAN ; VODUŠEK, DAVID B. ; ZIDAR, JANEZ ; MEH, DUŠKA ; Zorec, R (eds) ; Suput, D</creatorcontrib><description>Botulinum toxin therapy is safe and effective in the treatment of different movement disorders, especially focal dystonias. We reviewed botulinum toxin treatment of 97 patients: 36 had blepharospasm, 41 had torticollis, and 20 had diverse movement disorders. Patients with blepharospasm and torticollis improved markedly after botulinum toxin injections. The most common side effect in BS patients was ptosis (44.4%); in TC patients, it was dysphagia (29.3%). The mean duration of the improvement in both groups was 3.4 months. Very promising results were obtained also in the heterogeneous group including patients with other focal dystonias and cerebral palsy. On the basis of these results, we concluded that BTA injections must now be considered the mainstay of therapy for focal dystonias and other involuntary movement disorders.</description><identifier>ISSN: 0077-8923</identifier><identifier>ISBN: 9780897668521</identifier><identifier>ISBN: 0897668529</identifier><identifier>EISSN: 1749-6632</identifier><identifier>DOI: 10.1111/j.1749-6632.1994.tb26615.x</identifier><identifier>PMID: 8154763</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Blepharospasm - drug therapy ; Blepharospasm - physiopathology ; Botulinum Toxins - adverse effects ; Botulinum Toxins - therapeutic use ; Child ; Clostridium botulinum ; Female ; Humans ; Male ; Middle Aged ; Movement Disorders - drug therapy ; Movement Disorders - physiopathology ; Torticollis - drug therapy ; Torticollis - physiopathology</subject><ispartof>Annals of the New York Academy of Sciences, 1994-01, Vol.710 (1), p.76-87</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5336-170c29ba23e652546eb2e133b0ff804e37c14f4fce4ed1e2394bae5165206ee23</citedby><cites>FETCH-LOGICAL-c5336-170c29ba23e652546eb2e133b0ff804e37c14f4fce4ed1e2394bae5165206ee23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1749-6632.1994.tb26615.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1749-6632.1994.tb26615.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,1416,27924,27925,46049,46473</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8154763$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Zorec, R (eds)</contributor><contributor>Suput, D</contributor><creatorcontrib>DENIŠLIČ, MIRO</creatorcontrib><creatorcontrib>PIRTOŠEK, ZVEZDAN</creatorcontrib><creatorcontrib>VODUŠEK, DAVID B.</creatorcontrib><creatorcontrib>ZIDAR, JANEZ</creatorcontrib><creatorcontrib>MEH, DUŠKA</creatorcontrib><title>Botulinum Toxin in the Treatment of Neurological Disorders</title><title>Annals of the New York Academy of Sciences</title><addtitle>Ann N Y Acad Sci</addtitle><description>Botulinum toxin therapy is safe and effective in the treatment of different movement disorders, especially focal dystonias. We reviewed botulinum toxin treatment of 97 patients: 36 had blepharospasm, 41 had torticollis, and 20 had diverse movement disorders. Patients with blepharospasm and torticollis improved markedly after botulinum toxin injections. The most common side effect in BS patients was ptosis (44.4%); in TC patients, it was dysphagia (29.3%). The mean duration of the improvement in both groups was 3.4 months. Very promising results were obtained also in the heterogeneous group including patients with other focal dystonias and cerebral palsy. On the basis of these results, we concluded that BTA injections must now be considered the mainstay of therapy for focal dystonias and other involuntary movement disorders.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Blepharospasm - drug therapy</subject><subject>Blepharospasm - physiopathology</subject><subject>Botulinum Toxins - adverse effects</subject><subject>Botulinum Toxins - therapeutic use</subject><subject>Child</subject><subject>Clostridium botulinum</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Movement Disorders - drug therapy</subject><subject>Movement Disorders - physiopathology</subject><subject>Torticollis - drug therapy</subject><subject>Torticollis - physiopathology</subject><issn>0077-8923</issn><issn>1749-6632</issn><isbn>9780897668521</isbn><isbn>0897668529</isbn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><recordid>eNqVkF1r2zAUhsXW0aVZfkLB7GJ3dnX0afVi0O8WSnYxj7ErYTvHnTM7SiWbJf--Cgm5rxAI8b7nOfAQ8hVoBvFcLDPQwqRKcZaBMSIbKqYUyGzzgUyO0UcyMzqnudFK5ZLBCZlQqnWaG8Y_k7MQlpQCy4U-Jac5SKEVn5DLazeMXbsa-6Rwm3aVxDv8xaTwWA49robENckcR-8699LWZZfctsH5BfrwhXxqyi7g7PBOya_7u-LmMX3-8fB0c_Wc1pJzlYKmNTNVyTgqyaRQWDEEzivaNDkVyHUNohFNjQIXgIwbUZUoIZapwvifkm977tq71xHDYPs21Nh15QrdGCyoqEQYiMXLfbH2LgSPjV37ti_91gK1O5F2aXe27M6W3Ym0B5F2E4fPD1vGqsfFcfRgKubf9_n_tsPtO8h2_ufqZyRMSboHtGHAzRFQ-n9Waa6l_T1_sLIQcaEBW_A3Lv6O_A</recordid><startdate>19940101</startdate><enddate>19940101</enddate><creator>DENIŠLIČ, MIRO</creator><creator>PIRTOŠEK, ZVEZDAN</creator><creator>VODUŠEK, DAVID B.</creator><creator>ZIDAR, JANEZ</creator><creator>MEH, DUŠKA</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>C1K</scope></search><sort><creationdate>19940101</creationdate><title>Botulinum Toxin in the Treatment of Neurological Disorders</title><author>DENIŠLIČ, MIRO ; PIRTOŠEK, ZVEZDAN ; VODUŠEK, DAVID B. ; ZIDAR, JANEZ ; MEH, DUŠKA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5336-170c29ba23e652546eb2e133b0ff804e37c14f4fce4ed1e2394bae5165206ee23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Blepharospasm - drug therapy</topic><topic>Blepharospasm - physiopathology</topic><topic>Botulinum Toxins - adverse effects</topic><topic>Botulinum Toxins - therapeutic use</topic><topic>Child</topic><topic>Clostridium botulinum</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Movement Disorders - drug therapy</topic><topic>Movement Disorders - physiopathology</topic><topic>Torticollis - drug therapy</topic><topic>Torticollis - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DENIŠLIČ, MIRO</creatorcontrib><creatorcontrib>PIRTOŠEK, ZVEZDAN</creatorcontrib><creatorcontrib>VODUŠEK, DAVID B.</creatorcontrib><creatorcontrib>ZIDAR, JANEZ</creatorcontrib><creatorcontrib>MEH, DUŠKA</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Annals of the New York Academy of Sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DENIŠLIČ, MIRO</au><au>PIRTOŠEK, ZVEZDAN</au><au>VODUŠEK, DAVID B.</au><au>ZIDAR, JANEZ</au><au>MEH, DUŠKA</au><au>Zorec, R (eds)</au><au>Suput, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Botulinum Toxin in the Treatment of Neurological Disorders</atitle><jtitle>Annals of the New York Academy of Sciences</jtitle><addtitle>Ann N Y Acad Sci</addtitle><date>1994-01-01</date><risdate>1994</risdate><volume>710</volume><issue>1</issue><spage>76</spage><epage>87</epage><pages>76-87</pages><issn>0077-8923</issn><eissn>1749-6632</eissn><isbn>9780897668521</isbn><isbn>0897668529</isbn><abstract>Botulinum toxin therapy is safe and effective in the treatment of different movement disorders, especially focal dystonias. We reviewed botulinum toxin treatment of 97 patients: 36 had blepharospasm, 41 had torticollis, and 20 had diverse movement disorders. Patients with blepharospasm and torticollis improved markedly after botulinum toxin injections. The most common side effect in BS patients was ptosis (44.4%); in TC patients, it was dysphagia (29.3%). The mean duration of the improvement in both groups was 3.4 months. Very promising results were obtained also in the heterogeneous group including patients with other focal dystonias and cerebral palsy. On the basis of these results, we concluded that BTA injections must now be considered the mainstay of therapy for focal dystonias and other involuntary movement disorders.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>8154763</pmid><doi>10.1111/j.1749-6632.1994.tb26615.x</doi><tpages>12</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0077-8923
ispartof	Annals of the New York Academy of Sciences, 1994-01, Vol.710 (1), p.76-87
issn	0077-8923 1749-6632
language	eng
recordid	cdi_proquest_miscellaneous_16994491
source	Wiley-Blackwell Journals (Backfile Content)
subjects	Adolescent Adult Aged Aged, 80 and over Blepharospasm - drug therapy Blepharospasm - physiopathology Botulinum Toxins - adverse effects Botulinum Toxins - therapeutic use Child Clostridium botulinum Female Humans Male Middle Aged Movement Disorders - drug therapy Movement Disorders - physiopathology Torticollis - drug therapy Torticollis - physiopathology
title	Botulinum Toxin in the Treatment of Neurological Disorders
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T16%3A59%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Botulinum%20Toxin%20in%20the%20Treatment%20of%20Neurological%20Disorders&rft.jtitle=Annals%20of%20the%20New%20York%20Academy%20of%20Sciences&rft.au=DENI%C5%A0LI%C4%8C,%20MIRO&rft.date=1994-01-01&rft.volume=710&rft.issue=1&rft.spage=76&rft.epage=87&rft.pages=76-87&rft.issn=0077-8923&rft.eissn=1749-6632&rft.isbn=9780897668521&rft.isbn_list=0897668529&rft_id=info:doi/10.1111/j.1749-6632.1994.tb26615.x&rft_dat=%3Cproquest_cross%3E16994491%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5336-170c29ba23e652546eb2e133b0ff804e37c14f4fce4ed1e2394bae5165206ee23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=16994491&rft_id=info:pmid/8154763&rfr_iscdi=true